| Date | Title | Description |
| 26.06.2025 | Lupin launches generic chronic constipation treatment drug in US | - |
| 04.06.2025 | PE-owned Sekhmet Pharma gets former Lupin, Shilpa Medicare exec as new CEO | Santosh Kumar Mahil, managing director and CEO, Sekhmet Pharmaventures
A private equity consortium led by PAG, an Asia-focused investment firm, has announced the appointment of Santosh Kumar Mahil as managing director and CEO of Sekhmet Pha... |
| 15.05.2025 | Lupin clocks 113% growth in Q4 net profit at ₹782 crore | - |
| 15.05.2025 | Waters Corp's India business boosted by rush for weight-loss drugs | Waters Corp's India business boosted by rush for weight-loss drugs
By Kashish TandonMay 15, 202511:48 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Boxes of Ozempic and Wegovy made by Novo Nor... |
| 14.04.2025 | Dr Reddy’s layoffs: Pharma major to cut workforce cost by 25%? Here’s what the drugmaker says | Pharmaceutical layoffs planned? No, says Dr Reddy's Laboratories, as the drugmaker categorically denied media reports that has undertaken workforce reduction to cut costs by around 25 per cent. Calling the reports “factually incorrect”, Dr ... |
| 08.04.2025 | Lupin’s going beyond the pill to grow its digital therapeutics arm | - |
| 03.04.2025 | No tariffs on Indian pharma; plays vital role in supplying affordable medicines to US | New Delhi, Apr 3 (PTI) The Trump administration has exempted the Indian pharma sector from reciprocal tariffs, recognising the vital role played by the domestic industry in supplying affordable medicines across the globe, including the US, ... |
| 20.03.2025 | Eli Lilly brings much-awaited weight-loss drug Mounjaro to India | The much-awaited weightloss and diabetes drug, Mounjaro from US-based Eli Lilly and Company will be available at local chemists in a few weeks, at an India-specific price.
Globally Mounjaro, and peers in this category, Ozempic/Wegovy from N... |
| 20.03.2025 | Eli Lilly’s weight-loss drug Mounjaro comes to India, eyes big market with increasing obesity and diabetes risk | Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, March 20, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with high rates of obesity and di... |
| 17.02.2025 | Glenmark’s US plant to gain amid geopolitical shifts, says CMD | The evolving tariff situation in the US is “hard to predict”, Glenn Saldanha, Glenmark Pharma Chairman and Managing Director, told analysts. However, “given the geopolitical situation, we think Monroe should have a significant benefit, as w... |
| 02.01.2025 | Innovent and Roche: A New Dawn in Cancer Treatment | In the world of biopharmaceuticals, partnerships can spark innovation. Innovent Biologics, a rising star in the industry, has joined forces with Roche, a titan in oncology. Their collaboration centers on IBI3009, a novel antibody drug conju... |
| 30.12.2024 | Lupin acquires Huminsulin in India, from Eli Lilly | Drugmaker Lupin Ltd has acquired Huminsulin in India from Eli Lilly and Company, for an undisclosed amount. The move will strengthen Lupin’s diabetes footprint in the country.
Lupin has been marketing the Huminsulin range of products includ... |
| 14.12.2024 | Lupin acquires 3 anti-diabetes trademarks from Boehringer Ingelheim | Drugmaker Lupin acquires anti-diabetes trademarks Gibtulio, Gibtulio Met and Ajaduo from Boehringer Ingelheim International , strengthening its diabetes footprint in the country.
The trademark rights for these brands will be transferred to ... |
| 06.12.2024 | CloudThat Creates History as the First Indian Company to Win Consecutive AWS Training Partner Awards | Las Vegas, United States
CloudThat is excited to announce it is a recipient of the 2024 AWS Training Partner of the Year (APJ) Award, recognizing the top AWS Training Partners around the globe that have provided significant contributions re... |
| 25.11.2024 | Lupin recalls over 6 lakh bottles of hypertension drug in US: USFDA | Drug firm Lupin is recalling over six lakh bottles of a medication indicated for high blood pressure in the US due to deviation from current good manufacturing practices (CGMP), according to the US health regulator.
As per its latest Enforc... |
| 11.11.2024 | A guide to understanding NIFTY indices in India | Share
Tweet
Share
Share
Email
When it comes to investing in the Indian securities market, most retail and institutional investors look closely at the performance of the Nifty indices. The Nifty indices have become synonymous with the overal... |
| 08.11.2024 | Lupin aims to be part of ‘first wave of generics’ on GLP-1 products: Nilesh Gupta | Drugmaker Lupin aims to be part of the first wave of generic drugmakers to make GLP-1 receptor agonists products, used to treat Type II diabetes and obesity, Lupin top-brass said.
This segment of products includes semaglutide, the internati... |
| 05.08.2024 | Lupin completes Phase-III global trial on biosimilar of Lucentis | Drugmaker Lupin has completed advanced clinical trials (Phase III) of its biosimilar version of Roche’s Lucentis (ranibizumab), used to treat age-related macular degeneration (AMD).
About 600 patients from India, the US, the European Union ... |
| 18.07.2024 | Lupin partners with Huons to launch Cyclosporine Ophthalmic Nanoemulsion in Mexico | Lupin has signed a licence and supply agreement with Huons Co Ltd for the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion (0.4mL single-use vial) in Mexico.
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free nano... |
| 21.06.2024 | Weight-loss-drug frenzy lures rich Indians to brave the gray market | - |
| 17.06.2024 | GWEC India appoints Suzlon Group's Girish Tanti as new chair | Suzlon Vice Chairman Girish Tanti has been elected as the Chair of Global Wind Energy Council India (GWEC India), a statement said.
According to the industry body’s statement, he was elected Vice-Chair of GWEC in April.
The position plays a... |
| 17.06.2024 | Lupin appoints Abdelaziz Toumi as CEO of its new subsidiary | Global pharma major Lupin has appointed Abdelaziz Toumi as the Chief Executive Officer of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS).
The subsidiary is engaged in the development and sale of active pharmaceutical Ingre... |
| 09.06.2024 | Lupin recalls 51k bottles of generic antibiotic drug in US | Drug firm Lupin is recalling over 51,000 bottles of a generic antibiotic medication in the US market due to a "defective container", according to the American health regulator.
The US-based arm of the drug maker is recalling 51,00... |
| 05.06.2024 | Lupin strengthens global position with acquisition of Aarane and Nalcrom from Sanofi | Lupin has completed the acquisition of two brands from Sanofi—Aarane in Germany and Nalcrom in Canada and the Netherlands—along with the associated trademark rights.
Fabrice Egros, Lupin President (corporate development) said, the acquisiti... |
| 30.05.2024 | Why did investors dump Marksans Pharma shares post Q4 results? Know here | - |
| 29.05.2024 | Health secy highlights India's achievements, future goals at WHO assembly | - |
| 27.05.2024 | Indian pharmaceutical companies likely to cash in on US drug shortages | - |
| 24.05.2024 | Weak Q4 due to lower growth may be rare bitter pill for Sun Pharma | - |
| 21.05.2024 | Expect formulations biz to outpace API biz: Biocon Group CEO Peter Bains | - |
| 17.05.2024 | Indian pharma firms supplied 47% of all generic prescriptions in US in 2022 | - |
| 08.05.2024 | Dr Reddy's Labs slumps 5% as brokerages give 'Reduce' call post Q4 earnings | - |
| 07.05.2024 | IndiGo, Lupin, DCM Shriram and Gujarat Gas among six stocks to watch today | - |
| 07.05.2024 | Mid-day Mood | Sensex, Nifty extend losses amid broad-based selling | Indices fall amid broad based selling
Sensex and Nifty 50 extended losses on May 7 amid selling pressure across sectoral indices and in the broader market.
Barring Nifty FMCG, all major sectoral indices were in the red with Nifty Metal inde... |
| 07.05.2024 | Pharma major Lupin slides 5% as Q4 earnings miss street expectations | - |
| 06.05.2024 | Q4 Results Preview: Lupin may see strong topline, bottomline growth | - |
| 06.05.2024 | Dr Reddy's Q4 Preview: Here's what key brokerages expect from its results | - |
| 06.05.2024 | Q4FY24: Lupin, Godrej Consumer among 54 firms to report results on May 6 | - |
| 06.05.2024 | Lupin Q4 result: Net profit up 52% at Rs 359 cr, revenue from ops rises 12% | - |
| 04.05.2024 | India raises issue of pharma pricing control in Australia on generic drugs | - |
| 04.05.2024 | Productivity loss due to oral cancer in India in 2022 at $5.6 bn: Study | - |
| 02.05.2024 | India, New Zealand look to boost collaboration in pharma, digital trade | - |
| 01.05.2024 | Mizoram sees alarming surge in TB deaths, 108 succumb to disease in 2023 | - |
| 22.04.2024 | Lupin rises over 3% after US FDA approves Mirabegron tablets | - |
| 04.04.2024 | Lupin appoints Dr Ranjana Pathak as Chief Quality Officer | Drugmaker Lupin Limited has appointed Dr Ranjana Pathak as Chief Quality Officer, succeeding Johnny Mikell who will be retiring, the company said.
With over three decades of industry experience, Pathak will oversee all aspects of quality an... |
| 01.04.2024 | HAL soars 3%, hits 52 week high on highest ever revenue from operations | Shares of Hindustan Aeronautics Limited soared 2.80 per cent at Rs 3,420 a piece on Monday after the company declared a 11 per cent growth in operating revenue in financial year 2024. In comparison, the S&B BSE Sensex was up 0.57 per ce... |
| 26.03.2024 | Recovery in exports amid rising chemical prices to drive SRF stock | Shares of SRF, the country’s largest specialty chemicals player, hit a 10-month high last week on expectations that recovery in exports, amid rising prices, could aid sales revival.
Given expectations of higher realisations across its main ... |
| 19.03.2024 | Markets pricing NDA win in LS polls; eyeing budget proposals now: Analysts | The markets are already pricing in a victory for the Narendra Modi-led National Democratic Alliance (NDA) in the upcoming general elections, and expect the alliance to achieve its 400-seat target, suggest analysts.
More than the outcome of ... |
| 10.11.2022 | Form 483 cites Lupin manufacturing site in India for contamination and other quality control observations | The FDA has had its eye on the pharmaceutical manufacturer Lupin for a while, and now another facility for the company has been inspected by the US regulators and has revealed several quality control issues.
Acco... |
| 28.04.2022 | The revolving door swings again as Lupin hires an FDA official who oversaw problems at a key plant | The revolving door between the U.S. Food and Drug Administration and the pharmaceutical industry turned again this week when Lupin, one of India’s biggest drug companies, hired an agency official who oversaw manufacturing facilities, includ... |
| 19.04.2022 | Struggles with FDA continue for Lupin as it is handed another Form 483 | Troubled generics manufacturer Lupin has struggled with FDA cleaning and process validation guidelines for the past four years. Now, the Indian company’s been hit with another Form 483, following an inspection carried... |
| 09.02.2022 | Lupin : February 8, 2022 Lupin Receives Approval from U.S. FDA for Arformoterol Tartrate Inhalation Solution15 mcg (base)/2 ml | Mumbai, Baltimore, February 08, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Arformo... |
| 03.02.2022 | Lupin : February 3, 2022 Lupin Quarter 3 FY2022 Results | Mumbai, February 3, 2022: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending December 31, 2021. These unaudited results were taken on record by the Board of Directors at a meeting... |
| 27.01.2022 | Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® (secnidazole) expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis | BALTIMORE, Jan. 27, 2022 /PRNewswire/ -- Lupin Pharmaceuticals Inc., (Lupin), and Exeltis USA Inc. announced a promotional agreement for Exeltis to promote SOLOSEC® along with Exeltis' existing line of Women's Health products, further enhan... |
| 27.01.2022 | Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® (secnidazole) expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis | BALTIMORE, Jan. 27, 2022 /PRNewswire/ -- Lupin Pharmaceuticals Inc., (Lupin), and Exeltis USA Inc. announced a promotional agreement for Exeltis to promote SOLOSEC® along with Exeltis' existing line of Women's Health products, further enhan... |
| 19.01.2022 | Lupin : January 19, 2022 Lupin Signs First Partnership Agreement with Foncoo for China | Mumbai, Shanghai, January 19, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has entered into a partnership with Shenzhen Foncoo Pharmaceutical Co. Ltd (Foncoo). This is Lupin's first partnership arrangement in Chin... |
| 12.01.2022 | Lupin : Vinita Gupta at the JP Morgan Healthcare Conference Jan 12 2022 | J.P Morgan Healthcare
Conference
January 12th, 2022
Lupin Limited
Vinita Gupta, CEO
Safe Harbor Statement
Materials and information provided during this presentation may contain 'forward-looking statements'. These statements are based on cu... |
| 07.01.2022 | Lupin : January 7, 2022 Lupin launches Molnupiravir under the brand name Molnulup for the treatment of COVID-19 in adults in India | Clinical data suggests that it is effective on patients with co-morbidities
Mumbai, India, January 07, 2022: Global pharma major Lupin Limited (Lupin) announced the launch of Molnupiravir in India under the brand name Molnulup. This drug ha... |
| 25.12.2021 | Lupin : December 25, 2021 Lupin Receives Approval from U.S. FDA for Sevelamer Carbonate for Oral Suspension | Approval from Lupin's Goa Facility
Mumbai, Baltimore, December 25, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated N... |
| 24.12.2021 | Lupin : December 24, 2021 Lupin Receives Tentative Approval from U.S. FDA for Azilsartan Medoxomil Tablets | Mumbai, Baltimore, December 24, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA... |
| 14.12.2021 | Lupin : December 14, 2021 Lupin's Goa Manufacturing Plant Receives EIR from US FDA | FDA changes inspection classification of facility to Voluntary Action Indicated
Mumbai, December 14, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from United ... |
| 10.12.2021 | Lupin : December 10, 2021 Lupin Announces the Launch of its Diagnostics Business | Reaffirms its Commitment to Building an Integrated Healthcare Proposition in India
Mumbai, India, December 10, 2021: Global pharma major Lupin Limited (Lupin) today announced the launch of Lupin Diagnostics in India. As part of its strategy... |
| 02.12.2021 | Lupin : December 2, 2021 Lupin Partners with TTP plc UK for Soft-mist Inhalation Technology Platform | Mumbai, Somerset, New Jersey, December 02, 2021: Lupin Inc., a wholly-owned subsidiary of global pharma major, Lupin Limited (Lupin) has entered into an agreement with TTP plc (The Technology Partnership plc) to acquire the exclusive worldw... |
| 01.07.2021 | Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) for the Treatment of Trichomoniasis | |
| 17.06.2021 | LUPIN LIMITED
Lupin : Receives U.S. FDA Approval for Sevelamer Hydrochloride Tablets | Lupin Receives U.S. FDA Approval for Sevelamer Hydrochloride Tablets
Mumbai, Baltimore, June 17, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received approval for its Sevelamer Hydrochloride Tablets, 400 mg a... |
| 14.06.2021 | LUPIN LIMITED
Lupin : receives UK marketing authorization for Luforbec® 100/6 µg pMDI, first branded generic alternative to Fostair® 100/6 µg pMDI for treatment of Asthma & COPD | Lupin receives UK marketing authorization for Luforbec® 100/6 µg pMDI, first branded generic alternative to Fostair® 100/6 µg pMDI for treatment of Asthma & COPD
Mumbai, India | Slough, UK, June 14, 2021: Global pharma major, Lupin Limi... |
| 07.06.2021 | LUPIN LIMITED
Lupin : Launches Digital Asthma Educator platform | Lupin Launches Digital Asthma Educator platform
Mumbai, India, June 07, 2021: Global pharma major Lupin Limited (Lupin) today announced the launch of its Digital Asthma Educator platform. The platform guides asthma patients on the correct t... |
| 07.06.2021 | LUPIN LIMITED
Lupin : Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets | Lupin Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
Mumbai, Baltimore, June 07, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received approval for its Emtricitabine and... |
| 03.06.2021 | LUPIN LIMITED
Lupin : Launches Authorized Generic Version of Brovana® in the United States | Lupin Launches Authorized Generic Version of Brovana® in the United States
Mumbai, Baltimore, June 03, 2021: Global pharma major, Lupin Limited (Lupin), announced the launch of the authorized generic version of Brovana® (arformoterol tartra... |
| 02.06.2021 | LUPIN LIMITED
Lupin : announces U.S. FDA acceptance for Pegfilgrastim Biosimilar application | Lupin announces U.S. FDA acceptance for Pegfilgrastim Biosimilar application
Mumbai, Baltimore, June 2, 2021: Global pharma major, Lupin Limited (Lupin) today announced that the U.S. FDA has accepted the Biologics License Application (BLA) ... |
| 13.05.2021 | LUPIN LIMITED
Lupin : FINANCIAL YEAR 2021 | Investor Presentation Q4 FY2021
May 13, 2021
Safe Harbor Statement
Materials and information provided during this presentation may contain 'forward-looking statements'. These statements are based on current expectations, forecasts and assum... |
| 12.05.2021 | LUPIN LIMITED
Lupin : FY2021 Results | Lupin FY2021 Results
Mumbai, May 12, 2021: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter and fiscal year ending March 31, 2021. These audited results were taken on record by the Boa... |
| 01.02.2021 | Lupin Announces Partnership with Phil, Inc. in Support of SOLOSEC® (secnidazole) | |
| 16.11.2020 | Lupin Announces FDA Filing Acceptance of Supplemental New Drug Application for Solosec® (secnidazole) for the Treatment of Trichomoniasis | |
| 11.10.2017 | India’s Lupin bags Symbiomix and its newly approved antibiotic for $150M-plus | Just a few weeks after the FDA approved Symbiomix Therapeutics’ single-dose antibiotic Solosec (secnidazole) for a common form of gynecological infections, the American arm of India’s Lupin has stepped in to buy the ... |
| - | The choice behind hotel CIO Brian Kirkland’s all-in bet on cloud | Mere months after becoming chief information officer at Choice Hotels International, Brian Kirkland embarked on one of the most consequential projects that a CIO can undertake: getting out of the business of running data centers.
Beginning ... |
